Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common variable immunodeficiency (CVID) as defined by the Pan-American Group for Immunodeficiency (PAGID) and the European Society for Immunodeficiencies (ESID), or X-linked agammaglobulinemia (XLA) as defined by PAGID and ESID, or autosomal recessive agammaglobulinemia who have participated in the study ZLB06_001CR and who have tolerated IgPro well~* Written informed consent~Exclusion Criteria:~* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined as total urine protein concentration \> 0.2g/L)~* Other significant medical conditions that could increase the risk to the subject~* Females who are pregnant, breast feeding or planning a pregnancy during the course of the study~* Participation in a study with an investigational medicinal product within three months prior to enrollment, except for ZLB06_001CR~* Evidence of uncooperative attitude~* Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study~* Subjects who are employees at the investigational site, relatives or spouse of the investigator

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).

Based on this trial design, predict the completion outcome and termination type (if applicable).